Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 250

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 250
---
. Unless waived by Kadimastem, the obligations of Kadimastem to consummate the Merger are subject to the satisfaction of the following additional conditions: •the representations and warranties of NLS and Merger Sub shall be true and correct as of the Closing (subject to Material Adverse Effect); •NLS and Merger Sub shall have performed in all material respects their respective obligations and complied in all material respects with their respective covenants and agreements under the Merger Agreement required to be performed or complied with on or prior to the date of the Closing; •the absence of any Material Adverse Effect with respect to NLS, taken as a whole, since the date of the Merger Agreement which is continuing and uncured; •NLS shall have paid off, redeemed or satisfied all of its Vendor Indebtedness; •NLS shall have terminated the employment and engagement of all of its employees and consultants and paid or otherwise satisfied all back pay, severance or termination pay, vacation pay and all other liabilities in respect of all such employment and engagement; •Nasdaq shall have rescinded its notice to NLS, dated October28, 2024, as to NLS’s failure to satisfy Nasdaq criteria for listing and trade thereon; •NLS shall have at least USD $600,000 in gross funds (including cash in any of its bank accounts) plus any proceeds received by NLS from certain parties in connection with its financing transactions undertaken after the execution of the Merger Agreement; •The (i) directors of NLS immediately prior to the Effective Time shall have resigned from their positions (other than Mr. Zwyer), (ii) officers of NLS immediately prior to the Effective Time shall have resigned from their positions (other than Mr. Konofal who shall remain in a part -timeposition with NLS), (iii) the executive officers of Kadimastem immediately prior to the Effective Time shall be appointed as executive officers of NLS, and (iv) the Board shall call to convene an extraordinary shareholders’ meeting of NLS for the election of the board of directors as designated by Kadimastem immediately prior to the Effective Time to be elected as the Board; and •NLS Common Shares shall remain listed on the Nasdaq and shall not be subject to a delisting notice from Nasdaq. The notification form for the listing of NLS Common Shares to be issued in connection with the Merger shall have been accepted and approved (subject to official notice of issuance